NeuroRx announced today that it has been approved by the Nasdaq for listing, following the completion of its business combination with Big Rock Partners Acquisition. The combined entity is NRx Pharmaceuticals, and will trade under NRXP.
Closing the acquisition, valued at $500 million, represents the end of a bumpy road for the SPAC, which sought two deadline extensions, faced a Nasdaq delisting and weathered a law firm’s investigation of the deal.
NRx creates therapies to treat diseases where no medicines currently exist. Read more.
